TaiGen Biopharmaceuticals Holdings Limited (TPEX:4157)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
11.35
+0.05 (0.44%)
Mar 24, 2026, 1:30 PM CST
Market Cap8.04B -6.6%
Revenue (ttm)259.47M +72.2%
Net Income45.18M
EPS0.06
Shares Out711.83M
PE Ratio188.33
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume987,939
Average Volume1,569,640
Open11.40
Previous Close11.30
Day's Range11.25 - 11.45
52-Week Range7.44 - 16.40
Beta0.30
RSI40.80
Earnings DateMar 30, 2026

About TPEX:4157

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic foot infection; TG-1000, which is in phase III clinical trial to treat influenza A and B, and avian influenza H7N9; Furaprevir, a HCV protease inhibit... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Country Cayman Islands
Stock Exchange Taipei Exchange
Ticker Symbol 4157
Full Company Profile

Financial Performance

Financial Statements